Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLItm (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous ...